Novavax (NASDAQ: NVAX) reported Q2 EPS of ($6.53), $12.03 worse than the analyst estimate of $5.50. Revenue for the quarter came in at $186 billion versus the consensus estimate of $1.02 billion.

GUIDANCE:

Novavax sees FY2022 revenue of $2-2.3 billion, versus the consensus of $4.27 billion.

For earnings history and earnings-related data on Novavax (NVAX) click here.